Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Kathryn Therese. Mngadi"'
Autor:
John R. Mascola, Lily Zhang, Logashvari Naidoo, Erica Lazarus, David P. Burns, Myron S. Cohen, Michal Juraska, Yunda Huang, Lindsay N. Carpp, Kathryn Therese. Mngadi, Pedro Gonzales, April K. Randhawa, Julie E. Ledgerwood, Margarita M. Gomez Lorenzo, Allan C. deCamp, Nyaradzo Mgodi, Erika Rudnicki, Srilatha Edupuganti, Adrian B. McDermott, Shelly Karuna, Peter B. Gilbert, Philip Andrew, Lawrence Corey
Publikováno v:
EBioMedicine, Vol 64, Iss, Pp 103203-(2021)
EBioMedicine
EBioMedicine
The phase 2b AMP trials are testing whether the broadly neutralising antibody VRC01 prevents HIV-1 infection in two cohorts: women in sub-Saharan Africa, and men and transgender persons who have sex with men (MSM/TG) in the Americas and Switzerland.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66dc14768a759aec4f021f7fd44d67d7
http://www.sciencedirect.com/science/article/pii/S235239642030579X
http://www.sciencedirect.com/science/article/pii/S235239642030579X
Autor:
John R. Mascola, Myron S. Cohen, Yunda Huang, Kathryn Therese. Mngadi, Lindsay N. Carpp, Margarita M. Gomez Lorenzo, Erica Lazarus, Peter B. Gilbert, April K. Randhawa, David N. Burns, Srilatha Edupuganti, Pedro Gonzales, Erika Rudnicki, Julie E. Ledgerwood, Allan C. deCamp, Nyaradzo Mgodi, Lawrence Corey, Shelly Karuna, Logashvari Naidoo, Philip Andrew, Adrian B. McDermott, Michal Juraska, Lily Zhang
SummaryThe phase 2b AMP trials are testing whether the broadly neutralizing antibody VRC01 prevents HIV-1 infection in two cohorts: women in sub-Saharan Africa, and men and transgender persons who have sex with men (MSM/TG) in the Americas and Switze
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11a837252788dec916d34cd136124f6e
https://doi.org/10.1101/2020.09.02.20182881
https://doi.org/10.1101/2020.09.02.20182881
Autor:
Kathryn Therese. Mngadi, Vijay L. Mehra, Kristen W. Cohen, Glenda Gray, Shannon Grant, Zoe Moodie, Brodie Daniels, Marguerite Koutsoukos, Sanjay Phogat, Peter B. Gilbert, M. Juliana McElrath, Nonhlanhla N. Mkhize, Chenchen Yu, Georgia D. Tomaras, Olivier Van Der Meeren, Linda-Gail Bekker, James G. Kublin, Nicole Frahm, Carlos A. DiazGranados, Mary Allen, Lawrence Corey, Fatima Laher, Carter Bentley, Mookho Malahleha, Michael Pensiero, Lynn Morris, Kevin O. Saunders, Nicole L. Yates, Nicole Grunenberg, David C. Montefiori, Craig Innes
Publikováno v:
PLoS Medicine
PLoS Medicine, Vol 17, Iss 2, p e1003038 (2020)
PLoS Medicine, Vol 17, Iss 2, p e1003038 (2020)
Background HVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine regimen, investigating a 12-month booster to extend vaccine-induced immune responses. Methods and findings A phase 1–2 randomized double-blind place
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30ac6f0781ee1ce9f678bdbac01db968
http://europepmc.org/articles/PMC7039414
http://europepmc.org/articles/PMC7039414
Autor:
Quarraisha Abdool Karim, Nonhlanhla Yende-Zuma, Tanuja N. Gengiah, Gustavo F. Doncel, Kathryn Therese. Mngadi, Natasha Samsunder, Leila E. Mansoor, Jill L. Schwartz, Cheryl Baxter, Halima Dawood
Publikováno v:
Journal of the International AIDS Society
Introduction Tenofovir‐containing oral pre‐exposure prophylaxis (PrEP) is recommended for those at substantial risk as part of combination HIV prevention. However, there are limited data, beyond clinical trial settings, to guide the introduction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74ccc31af9d366f9a164596f8b3c5dbb
http://europepmc.org/articles/PMC6737288
http://europepmc.org/articles/PMC6737288
BACKGROUND Accurate safety monitoring in HIV vaccine trials is vital to eventual licensure and consequent uptake of products. Current practice is to capture related side effects in a hardcopy tool, reconciled post vaccination, which is time-consuming
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a48035d6acc595c2482a8a628eddcef9
https://doi.org/10.2196/preprints.9396
https://doi.org/10.2196/preprints.9396
Autor:
Nivashnee Naicker, Anne Rompalo, R Noble, Natasha Samsunder, Adrian Mindel, Nigel Garrett, Kaymarlin Govender, Leila E. Mansoor, Kathryn Therese. Mngadi, Jessica Naidoo, Nokukhanya Ngubane
Publikováno v:
Epidemiology, Monitoring and Evaluation.
Introduction Accurate HIV risk assessment is essential when screening volunteers for HIV prevention studies. STI testing plays a key role, but has traditionally been conducted in central laboratories resulting in reporting delays, which can impact on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffa32d3b4ccf560492c24e3d0ff2b815
https://doi.org/10.1136/sextrans-2017-053264.344
https://doi.org/10.1136/sextrans-2017-053264.344
Publikováno v:
The CAPRISA Clinical Trials: HIV Treatment and Prevention ISBN: 9783319475172
Despite a trend of declining HIV incidence rates, up to 2 million people continue to become newly infected with HIV every year. Antiretroviral-based interventions offer optimism to achieve epidemic control, but a vaccine is needed to eliminate HIV. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdb0334a07552330ef5b9d8df07715a1
https://doi.org/10.1007/978-3-319-47518-9_7
https://doi.org/10.1007/978-3-319-47518-9_7
Publikováno v:
The CAPRISA Clinical Trials: HIV Treatment and Prevention ISBN: 9783319475172
Product effectiveness in “real-world” settings in healthcare services may differ markedly from product efficacy observed in clinical trials. Limited data exists, beyond clinical trial settings, to guide the introduction of pre-exposure prophylaxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a184432bf1fa64262750ebc2ed1af7b3
https://doi.org/10.1007/978-3-319-47518-9_5
https://doi.org/10.1007/978-3-319-47518-9_5
Autor:
Lawrence Corey, Linda-Gail Bekker, Fatima Laher, M. Julie McElrath, Barbara Metch, Peter B. Gilbert, Gavin J. Churchyard, James G. Kublin, Matsontso Mathebula, Surita Roux, Michael N. Robertson, Craig Innes, Maphoshane Nchabeleng, Kathryn Therese. Mngadi, Glenda E. Gray, Koleka Mlisana, Zoe Moodie, Mary Allen
Publikováno v:
The Lancet Infectious Diseases. 14:388-396
Summary Background The HVTN 503/Phambili study, which assessed the efficacy of the Merck Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine in South Africa, was stopped when futility criteria in the Step study (assessing the same vaccine in the Ameri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5bdadee6fb2763501da369bc685a24a
https://doi.org/10.1016/s1473-3099(14)70020-9
https://doi.org/10.1016/s1473-3099(14)70020-9
Publikováno v:
Journal of medical ethics. 43(12)
Participant safety and data integrity, critical in trials of new investigational drugs, are achieved through honest participant report and precision in the conduct of procedures. HIV prevention post-trial access studies in middle-income countries pot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1666b477d02a80073d7cb4e5876d5952
https://pubmed.ncbi.nlm.nih.gov/28739638
https://pubmed.ncbi.nlm.nih.gov/28739638